Status:
COMPLETED
Airway Microbiome and Th17-mediated Inflammation in COPD Among HIV-infected Individuals in a Rural Ugandan Cohort
Lead Sponsor:
Makerere University
Collaborating Sponsors:
Charite University, Berlin, Germany
Conditions:
COPD
HIV Infections
Eligibility:
All Genders
35-100 years
Brief Summary
Rationale: COPD is increasing in prevalence among people living with HIV/AIDS (PLWHA) as widespread use of ART has increased longevity in this population. In rural Ugandan ART clinics, we report COPD ...
Detailed Description
Introduction The improvement in access to antiretroviral therapy (ART) among people living with HIV/AIDs (PLWHA) has resulted in a decrease in HIV-associated morbidity and mortality\[1\]. This is part...
Eligibility Criteria
Inclusion
- We will consider samples from Male and female HIV-seropositive and negative individuals ≥35 years who have been screened for COPD as per standard guidelines (European Respiratory Society, ERS, and American Thoracic Society, ATS) using the modified Burden of lung diseases (BOLD) questionnaire and spirometry.
Exclusion
- We will exclude samples from subjects with asthma, significant chronic respiratory disease other than COPD or unable to give informed consent.
Key Trial Info
Start Date :
April 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2023
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT05223114
Start Date
April 1 2022
End Date
January 31 2023
Last Update
June 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Makerere University Lung Institute
Kampala, Uganda, 256